Immuno-oncology

 

In today’s episode, we will start with a quick introduction to Immuno-Oncology. We will then look in to the evolution of this concept followed by the current situation and finally, we will touch briefly on the road-ahead for Immuno-Oncology. We would love to hear from our audiences on which Immuno-oncology therapies you think have shaped today's treatment paradigm?

Founded in 2014, RAS is a boutique strategy consulting firm dedicated to providing bench-to-bedside decision support to pharmaceutical, biotech, and medical device companies via Information and Strategy Support services. We specialize in executing customer and competitive research projects in Oncology, Ophthalmology, Neuroscience, Diabetes, Cardiovascular, Biosimilars, and more. In our series, we will discuss and provide guidance on issues related to strategy and execution. We will cover topics such as product strategy, clinical development, launch readiness, and much more. From the latest groundbreaking discoveries in biology to changes in government regulations, our conversations are always evolving.

TIMESTAMPS

0:00 Introduction

0:55 Immuno-Oncology Definition

3:17 Immuno-Oncology Therapies and Success rate

5:02 Evolution of Immuno-Oncology

9:08 Back to Limelight

10:06 USFDA Approved Immunotherapeutics

12:15 Immunotherapeutics Success rate

14:12 Hot vs Cold Tumors

17:00 Immunotherapeutics - Ongoing Research and Progress

Immuno-oncology